keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tat-CIRP是一种肽类抑制剂,用于抑制髓样分化2蛋白(MD-2,亦称淋巴细胞抗原96 [LY96])与寒冷诱导的RNA结合蛋白(CIRP)之间的蛋白-蛋白相互作用。它通过与MD-2结合,干扰MD-2与CIRP之间的相互作用,这一作用在共免疫沉淀实验中得到证实。在体内实验中,Tat-CIRP (10及20 mg/kg) 能够减少由中脑动脉闭塞(MCAO)引发的小鼠脑梗死体积。同样,在通过血栓引发脑梗死的恒河猴模型中,Tat-CIRP同样能减少脑梗死体积,并缩短患中风一侧手臂抓取并放下食物的时间。
产品描述 | Tat-CIRP, a peptide inhibitor, impedes the protein-protein interaction between myeloid differentiation 2 (MD-2), also known as lymphocyte antigen 96 (LY96), and cold-inducible RNA binding protein (CIRP) by binding to MD-2. This disrupts the MD-2 and CIRP interaction as confirmed in co-immunoprecipitation assays. Notably, in vivo studies reveal that Tat-CIRP, at dosages of 10 and 20 mg/kg, significantly reduces infarct volume in both a mouse model of middle cerebral artery occlusion (MCAO) and a rhesus monkey model of thrombosis-induced stroke. Additionally, it improves motor function, evidenced by decreased time to manipulate and withdraw food with the affected arm in the primate model. |
别名 | Tat-Cold-inducible RNA Binding Protein |
分子量 | 2997.30 |
分子式 | C123H206N56O33.XCF3COOH |
keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: soluble
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tat-CIRP TFA Tat-Cold-inducible RNA Binding Protein Inhibitor inhibitor inhibit